Publications by authors named "Shintaro Saito"

16 Publications

  • Page 1 of 1

Prognostic factors for refractory pheochromocytoma and paraganglioma after I-metaiodobenzylguanidine therapy.

Ann Nucl Med 2021 Oct 13. Epub 2021 Oct 13.

Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Objective: Given the rarity of refractory pheochromocytoma and paraganglioma (PPGL), outcomes and prognostic factors after I-metaiodobenzylguanidine (I-mIBG) treatment still remain unclear. Therefore, this study evaluated whether baseline characteristics at initial I-mIBG therapy and imaging response to repeated I-mIBG therapy could be prognostic factors for refractory PPGL.

Methods: All patients [n = 59 (male/female = 35/24), median age; 49.3 years] with refractory PPGL who received I-mIBG therapy at our institution between September 2009 and September 2019 were retrospectively reviewed for the effects of the following factors on overall survival: age, sex, hypertension, diabetes mellitus, palpitations, constipation, cancer pain, catecholamines values, past history of therapy (external beam radiation for bone metastasis, operation, and chemotherapy), metastasis sites, and response to I-mIBG treatments.

Results: Throughout the follow-up period, 18 patients died from disease exacerbation. The estimated 5- and 10-year survival rates were 79.4% and 67.2% from the initial diagnoses of refractory PPGL and 68.5% and 49.9% from the first I-mIBG therapy, respectively. The multivariate Cox proportional hazards model showed that progressive disease (PD) [hazard ratio (HR) 96.3, P = 0.011] and constipation (HR 8.2, P = 0.024) were adverse prognostic factors for overall survival after initial I-mIBG therapy. The log-rank test demonstrated that PD in response to I-mIBG therapies (P < 0.0001) and constipation (P < 0.01) were correlated with poor survival rates.

Conclusions: Response to repeated I-mIBG treatment can be a strong predictor of prognosis after initial I-mIBG therapy for refractory PPGL. Repeated I-mIBG therapy may be a good option for controlling refractory PPGL.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-021-01685-6DOI Listing
October 2021

Convolutional neural network-based automatic heart segmentation and quantitation in I-metaiodobenzylguanidine SPECT imaging.

EJNMMI Res 2021 Oct 12;11(1):105. Epub 2021 Oct 12.

Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan.

Background: Since three-dimensional segmentation of cardiac region in I-metaiodobenzylguanidine (MIBG) study has not been established, this study aimed to achieve organ segmentation using a convolutional neural network (CNN) with I-MIBG single photon emission computed tomography (SPECT) imaging, to calculate heart counts and washout rates (WR) automatically and to compare with conventional quantitation based on planar imaging.

Methods: We assessed 48 patients (aged 68.4 ± 11.7 years) with heart and neurological diseases, including chronic heart failure, dementia with Lewy bodies, and Parkinson's disease. All patients were assessed by early and late I-MIBG planar and SPECT imaging. The CNN was initially trained to individually segment the lungs and liver on early and late SPECT images. The segmentation masks were aligned, and then, the CNN was trained to directly segment the heart, and all models were evaluated using fourfold cross-validation. The CNN-based average heart counts and WR were calculated and compared with those determined using planar parameters. The CNN-based SPECT and conventional planar heart counts were corrected by physical time decay, injected dose of I-MIBG, and body weight. We also divided WR into normal and abnormal groups from linear regression lines determined by the relationship between planar WR and CNN-based WR and then analyzed agreement between them.

Results: The CNN segmented the cardiac region in patients with normal and reduced uptake. The CNN-based SPECT heart counts significantly correlated with conventional planar heart counts with and without background correction and a planar heart-to-mediastinum ratio (R = 0.862, 0.827, and 0.729, p < 0.0001, respectively). The CNN-based and planar WRs also correlated with and without background correction and WR based on heart-to-mediastinum ratios of R = 0.584, 0.568 and 0.507, respectively (p < 0.0001). Contingency table findings of high and low WR (cutoffs: 34% and 30% for planar and SPECT studies, respectively) showed 87.2% agreement between CNN-based and planar methods.

Conclusions: The CNN could create segmentation from SPECT images, and average heart counts and WR were reliably calculated three-dimensionally, which might be a novel approach to quantifying SPECT images of innervation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-021-00847-xDOI Listing
October 2021

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.

Eur J Cancer 2021 Sep 23;157:361-372. Epub 2021 Sep 23.

Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan. Electronic address:

Background: Immune checkpoint inhibitors (ICIs) have a lower efficacy in mucosal melanoma (MUM) than in cutaneous melanoma. The use of combination treatments with radiotherapy (RT) to improve the efficacy in MUM, however, requires further investigation.

Methods: We retrospectively evaluated 225 advanced MUM patients treated with anti-PD-1 monotherapy (PD1; 115) or anti-PD-1 + anti-CTLA-4 combination therapy (PD1+CTLA4; 42) with or without RT (56 and 12, respectively). Treatment efficacy was estimated by determining the objective response rate (ORR) and survival rate with the Kaplan-Meier analysis.

Results: The baseline characteristics between the two groups in each ICI cohort were similar, except for Eastern Cooperative Oncology Group performance status in the PD1 cohort. No significant differences in ORR, progression-free survival (PFS), and overall survival (OS) were observed between the PD1 alone and PD1+RT groups in the PD1 cohort (ORR 26% versus 27%, P > 0.99; median PFS 6.2 versus 6.8 months, P = 0.63; median OS 19.2 versus 23.1 months, P = 0.70) or between the PD1+CTLA alone and PD1+CTLA4+RT groups in the PD1+CTLA4 cohort (ORR 28% vs 25%, P = 0.62; median PFS 5.8 versus 3.5 months, P = 0.21; median OS 31.7 versus 19.8 months, P = 0.79). Cox multivariate analysis indicated that RT in addition to PD1 or PD1+CTLA4 did not have a positive impact on the PFS or OS.

Conclusions: A prolonged survival benefit with RT in combination with ICIs was not identified for advanced MUM patients, although RT may improve local control of the tumour and relieve local symptoms.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2021.08.034DOI Listing
September 2021

Comparison of the detecting capability between I-mIBG and post-therapeutic I-mIBG scintigraphy for curie scoring in patients with neuroblastoma after chemotherapy.

Ann Nucl Med 2021 Jun 17;35(6):649-661. Epub 2021 Apr 17.

Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Objective: To evaluate the detecting capability between planar imaging (PI) and PI combined with single-photon emission computed tomography/computed tomography (PICWS), including I- and I-labeled metaiodobenzylguanidine (mIBG) and to compare the detecting capability between I-mIBG and post-therapeutic I-mIBG scintigraphy including PI and PICWS for Curie scoring in patients with neuroblastoma.

Methods: Sixty-two patients with 66 pairs of complete images with neuroblastoma were enrolled in this retrospective study.

Results: Comparing the Curie scoring between I-mIBG PI and PICWS and between post-therapeutic I-mIBG PI and PICWS, findings were concordantly negative in 28.79% and 18.18% of studies, concordantly positive in 66.67% and 74.24% of studies, and discordant in 4.54% and 7.58% of studies, respectively. PICWS was superior to PI including I- and I-mIBG in the evaluation of Curie scoring for neuroblastoma patients (both P < 0.001). Comparing the Curie scores between I- and post-therapeutic I-mIBG PI and between I- and post-therapeutic I-mIBG PICWS, concordantly negative imaging was visualized in 22.73% and 19.70% of studies, concordantly positive imaging in 66.67% and 69.70% of studies, and discordant imaging in 10.60% and 10.60% of studies, respectively. Post-therapeutic I-mIBG was significantly better than that of I-mIBG scintigraphy including PI and PICWS in detecting the Curie scoring for neuroblastoma patients (both P < 0.001).

Conclusion: The present study demonstrates that I- or I-mIBG PICWS are more helpful in the evaluation of Curie scores than that of conventional PI and that post-therapeutic I-mIBG is superior to I-mIBG scintigraphy for the detecting capability of Curie scoring in patients with neuroblastoma.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-020-01569-1DOI Listing
June 2021

Diagnostic Use of Post-therapy I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma.

Diagnostics (Basel) 2020 Sep 2;10(9). Epub 2020 Sep 2.

Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.

I-meta-iodobenzylguanidine (I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy I-mIBG scintigraphy may detect more lesions compared with diagnostic I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic I-mIBG scintigraphy. We retrospectively examined the diagnostic utility of post-therapy I-mIBG scintigraphy in children who received I-mIBG as consolidation therapy. Nineteen children with complete response to primary therapy were examined. Post-therapy I-mIBG scintigraphy was performed four days after injection. The post-therapy I-mIBG scintigraphy, 4 children exhibited abnormal uptake on the WBS. Post-therapy I-mIBG SPECT/CT provided additional information in 2 cases. In total, 6 children exhibited abnormal uptake. The site of abnormal accumulation was on the recurrence site in one case, operation sites in five cases, and bone metastasis in one case. Post-therapy I-mIBG scintigraphy could detect residual disease that was not recognized using diagnostic I-mIBG scintigraphy in 32% of children with high-risk neuroblastoma and ganglioneuroblastoma. The diagnostic use of post-therapy I-mIBG scintigraphy can provide valuable information for detecting residual disease.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10090663DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555271PMC
September 2020

High-dose I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience.

Ann Nucl Med 2020 Nov 29;34(11):840-846. Epub 2020 Aug 29.

Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Objective: Children with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose I-meta-iodo-benzyl-guanidine (I-mIBG) in relapsed neuroblastoma or ganglioneuroblastoma patients with complete response (CR) to induction therapy as demonstrated by diagnostic I-mIBG scintigraphy.

Methods: Between December 2009 and 2014, five patients with relapsed neuroblastoma and one with relapsed ganglioneuroblastoma received high-dose I-mIBG therapy. Overall and progression-free survival rates at five years after I-mIBG therapy were analyzed by the Kaplan-Meier method.

Results: During follow-up, three children showed no signs of disease relapse, whereas three died. One child without a relapse died from post-transplant side effects, and two children with a relapse died owing to tumor progression. The 5-year progression-free and overall survival rates after I-mIBG therapy were 44% and 67%, respectively.

Conclusions: Consolidation therapy with high-dose I-mIBG for patients with 2 CR showed good overall and progression-free survival. While the risks of radiation exposure must be considered, high-dose I-mIBG therapy as consolidation therapy needs to be further investigated.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-020-01514-2DOI Listing
November 2020

Prediction of the invasive level of basal cell carcinomas in the facial area: Analysis of 718 Japanese cases.

J Dermatol Sci 2020 Sep 4;99(3):152-157. Epub 2020 Jul 4.

Department of Dermato-Oncology / Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

Background: Basal cell carcinoma (BCC) is the most common skin cancer. While Mohs micrographic surgery is commonly accepted for BCC treatment, surgical excision with free margins is widely considered the best treatment modality for BCCs in Japan. However, little is known about the predictors of the invasion levels of BCCs.

Objective: To investigate the optimization of deep surgical margins by identifying factors significantly influencing the invasion levels of facial BCCs.

Methods: The tumor invasion level was defined as the deepest part of a tumor. Tumor thickness was measured from the top of the granular layer to the deepest extension of the tumor or from the ulcer base overlying the deepest point of invasion in ulcerated lesions. Factors independently associated with tumor thickness and invasion level were identified by multivariate analysis. Six variables were tested: age, sex, anatomical region (nose, orbit, others), histologic pattern (aggressive, non-aggressive), presence of pigmentation, and diameter.

Results: We included 718 cases of facial BCCs involving 705 Japanese patients. The most frequent anatomical region and histologic pattern were the nose and nodular pattern, respectively. Only tumor diameter showed a correlation with tumor thickness (β = 0.377, P < 0.001). Tumor diameter (AOR = 71.189, 95 % CI: 11.420-430.931, P = 0.01) and the following anatomical regions showed correlations with the invasion level: nose/others: AOR=2.769, 95 % CI: 1.235-6.493, P = 0.01; orbit/others: AOR=6.369, 95 % CI: 2.728-15.429, P < 0.001; orbit/nose: AOR=2.300, 95 % CI: 1.056-4.984, P = 0.04.

Conclusions: This study serves as a guide for optimizing deep surgical margins and planning surgery for facial BCCs considering independently associated factors.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.07.001DOI Listing
September 2020

Soy β-Conglycinin Peptide Attenuates Obesity and Lipid Abnormalities in Obese Model OLETF Rats.

J Oleo Sci 2020 ;69(5):495-502

Department of Biological Resource Science, Saga University.

We previously reported that soy β-conglycinin (βCG) improves obesity-induced metabolic abnormalities, but not obesity, in obese model Otsuka Long-Evans Tokushima fatty (OLETF) rats. In the present study, we aimed to investigate the effects of βCG-derived peptide consumption on obesity and lipid abnormality in OLETF rats. To this end, wild-type Long-Evans Tokushima Otsuka and OLETF rats were provided a normal diet containing 20% casein for four weeks as a control. In addition, we prepared βCG peptide by enzymatic hydrolysis, and OLETF rats were fed a diet in which half of the casein was replaced by βCG peptide (βCG peptide group). Consequently, rats in the βCG peptide group showed decreased abdominal white adipose tissue weight and lipid content (serum and liver triglycerides, and serum and liver cholesterol) compared to control OLETF rats. Further analysis demonstrated that βCG peptide consumption decreased lipogenic enzyme activity and increased lipolytic enzyme activity in the liver of OLETF rats. In addition, suppressive effects on both synthesis and absorption of cholesterol were observed in βCG peptide-fed OLETF rats. These findings suggest that peptidization of βCG enhanced the anti-obese and hypolipidemic effects of βCG.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5650/jos.ess20010DOI Listing
September 2020

High-dose I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan.

Ann Nucl Med 2020 Jun 26;34(6):397-406. Epub 2020 Mar 26.

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Objective: The aim of the study was to investigate the outcomes and prognostic factors of high-dose I-metaiodobenzylguanidine (I-MIBG) therapy in patients with refractory or relapsed neuroblastoma (NBL) in Japan.

Methods: We retrospectively analyzed 20 patients with refractory or relapsed high-risk NBL who underwent I-MIBG therapy with an administration dose ranging from 444 to 666 MBq/kg at Kanazawa University Hospital, Japan, between September 2008 and September 2013. We focused on measurements regarding their initial responses, prognostic factors, survivals, and toxicities following I-MIBG therapy using our hospital data and questionnaires from the hospitals that these patients were initially referred from. Furthermore, we performed Kaplan-Meier survival analysis to evaluate event-free survival (EFS) and overall survival (OS).

Results: In 19 patients with complete follow-up data, the median age at first I-MIBG treatment was 7.9 years (range 2.5-17.7 years). Following I-MIBG therapy, 17 of the 19 patients underwent stem-cell transplantations, and their treatment response was either complete (CR) or partial (PR) in three and two cases, respectively. The EFS and OS rates at 1 year following I-MIBG therapy were 42% and 58%, respectively, and those at 5 years following I-MIBG therapy were 16% and 42%, respectively. Using the two-sample log-rank test, the OS time following I-MIBG therapy was significantly longer for < 3-year time interval between the initial diagnosis and I-MIBG therapy (p = 0.017), Curie score < 16 just before I-MIBG therapy (p = 0.002), without pain (p = 0.002), without both vanillylmandelic acid (VMA) and homovanillic acid (HVA) elevation (p = 0.037) at I-MIBG therapy, and with CR or PR following I-MIBG therapy (p = 0.015). Although severe hematological toxicities were identified in all 19 patients, severe nonhematological toxicity was not recorded in any patient, except for one patient with grade 3 anorexia and nausea.

Conclusions: High-dose I-MIBG therapy in patients with refractory or relapsed high-risk NBL can provide a favorable prognosis without severe nonhematological toxicities. Better prognosis may be anticipated in patients with the initial good response, no pain at I-MIBG therapy, no VMA and HVA elevation at I-MIBG therapy, low Curie score (< 16) just before I-MIBG therapy, and short time interval (< 3 years) between the initial diagnosis and I-MIBG therapy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-020-01460-zDOI Listing
June 2020

[Proposal of Information Management Method in Heat Generation of Magnetic Resonance Examination].

Nihon Hoshasen Gijutsu Gakkai Zasshi 2019 ;75(11):1347-1354

Department of Radiology, Yamagata Prefectural Shinjo Hospital.

The safety management information related to heat generation in magnetic resonance imaging (MRI) examinations includes the specific absorption rate (SAR), the root mean square (RMS) of the MRI effective component of the B field (B1+rms), and imaging time, which must be set appropriately before an MRI examination. However, unlike image attributes and data, these three parameters do not require any image storage; therefore, information collection and confirmation post-inspection are difficult. Therefore, in this study, we used Digital Imaging and Communications in Medicine of SAR and imaging time using the overlay function of the picture archiving and communication systems (PACS) to confirm the specific absorption rate B1+rms and imaging time post-inspection. The medicine identification tag information was displayed on the PACS viewer. For some imaging times, the console display during scanning and the PACS viewer display did not match. However, the SAR console display during scanning and the PACS viewer display matched well, thereby rendering it easier to manage safety in MRI examinations.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.6009/jjrt.2019_JSRT_75.11.1347DOI Listing
December 2019

Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.

J Dermatol 2018 Mar 22;45(3):349-352. Epub 2017 Nov 22.

Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.

We recently identified the efficacy and safety of a botulinum toxin (BTX)-A/B in Raynaud's phenomenon (RP) and digital ulcers (DU) in Japanese patients with systemic sclerosis (SSc). Detailed assessments of peripheral vascular disorder using angiography and dermoscopic images of nail fold capillaries have not been performed previously. This study aimed to evaluate the effect of BTX-B on SSc-associated peripheral vascular disorder. Two SSc patients who suffered with RP and DU were treated with a BTX-B injection, and thereafter the symptoms of RP were improved and DU healed in both patients. Furthermore, angiography showed an increased blood flow to the palm and fingers, and dermoscopic images of nail fold capillary changes showed improvement. These results suggest that a BTX-B injection may increase peripheral blood flow and improve RP and DU in SSc patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14140DOI Listing
March 2018

Soy β-conglycinin improves obesity-induced metabolic abnormalities in a rat model of nonalcoholic fatty liver disease.

Obes Res Clin Pract 2015 Mar-Apr;9(2):168-74. Epub 2014 Apr 29.

Basic Research Institute, R&D, Fuji Oil Co., Ltd., 4-3 Kinunodai, Tsukubamirai-shi, Ibaraki 300-2497, Japan.

Nonalcoholic fatty liver disease (NAFLD) has a variety of causes including calorie over-intake, an unbalanced diet, and/or genetic dysfunction of lipid metabolism. We hypothesized that NAFLD symptoms could be mitigated by specific nutritional factors. Here, we show that the potential for soy β-conglycinin (βCG) to improve obesity-induced metabolic abnormalities in the Otsuka Long Evans Tokushima fatty (OLETF) rat model of NAFLD. Long Evans Tokushima Otsuka (i.e., wild-type) and OLETF rats were provided a normal diet containing 20% casein for 4 weeks as a control. In a third (βCG) group, OLETF rats were fed a diet in which half of the casein was replaced by βCG. There was no difference in food intake between groups. Rats in the βCG group had decreased liver weight and lipid content (triglycerides, cholesterol, and phospholipids) compared to controls. In addition, βCG consumption decreased fatty acid synthase gene expression and enzymatic activity. These findings indicate that dietary intake of βCG can improve obesity-induced metabolic dysfunction, possibly via suppression of de novo fatty acid synthesis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.orcp.2014.03.005DOI Listing
December 2015

Simultaneous analysis of acidulants and preservatives in food samples by using capillary zone electrophoresis with indirect UV detection.

Food Chem 2011 Aug 1;127(3):1385-90. Epub 2011 Feb 1.

Department of Materials and Applied Chemistry, College of Science and Technology, Nihon University, 1-8-14, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8308, Japan.

Capillary zone electrophoresis with indirect UV detection was developed for the simultaneous analysis of acidulants and preservatives in food samples. When a solution of tris (hydroxymethyl) aminomethane, trimellitic acid and poly (vinyl alcohol) was used as the background electrolyte, the nine acidulants and four preservatives listed in the Japanese Food Sanitation Law were detected within 8min. The calibration curves plotted from the peak height of each analyte were linear with a correlation coefficient of 0.99. The relative standard deviations (n=10) of the peak height ranged from 1.2% to 4.7%. The detection limits for these species ranged from 0.6 to 5.3mg/L at a signal-to-noise ratio of three. The method developed method was applied to the simultaneous analysis of acidulants and preservatives in a wide variety of food samples.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.foodchem.2011.01.126DOI Listing
August 2011

Diastereoselective synthesis of D- and L-myo-inositol 3,4,5,6-tetrakisphosphates from D-glucose via dihydroxylation of (+)-conduritol B derivatives.

Chem Pharm Bull (Tokyo) 2004 Jun;52(6):727-32

Research and Education Center for Materials Science, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma, Nara 630-0101, Japan.

Syntheses of D- and L-myo-inositol 3,4,5,6-tetrakisphosphates were achieved via diastereoselective 1,2-addition of vinylcopper reagent with the chiral aldehyde prepared from 1,2,5,6-diisopropylidene-D-glucose, ring-closing metathesis of 1,7-diene with Grubbs catalyst followed by catalytic OsO(4) dihydroxylation of (+)-conduritol B derivatives.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.52.727DOI Listing
June 2004
-->